Catheters linked with high risk of infections, heart problems, and death in dialysis patients

February 21, 2013

Dialysis patients using catheters to access the blood have the highest risks for death, infections, and cardiovascular events compared with patients using other types of vascular access, according to an analysis appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The authors note that more research is needed to determine individual patients' risks, however.

For patients who must undergo dialysis, experts recommend an arteriovenous fistula, which is created by connecting patient's own vein and artery to form a long-lasting site through which blood can be removed and returned. Alternatively, a patient may use an arteriovenous graft, which is a plastic conduit between an artery and a vein. Many patients use a catheter instead for several reasons, including inadequate preparation for dialysis, avoidance of surgery or fear of needles, as attachment to the via a catheter does not require needles. Also, an arteriovenous fistula or graft is not possible in all patients, especially those who are sicker.

To compare different types of vascular access for dialysis, Pietro Ravani, MD, PhD (University of Calgary, Canada) and his colleagues reviewed the , evaluating the associations between arteriovenous fistula, arteriovenous graft, and central venous catheter with risk for death, infection, and major heart-related events such as heart attacks and strokes. The researchers identified 67 studies comprising 586,337 participants.

Among the major findings:

  • Compared with individuals with fistulas, those using catheters had a 38% higher risk of experiencing a major heart-related event, a 53% higher risk of dying, and more than double the risk of developing .
  • Compared with individuals with fistulas, those with grafts had an 18% increased risk of dying and a 36% increased risk of developing fatal infections, but they did not have an increased risk of experiencing a major heart-related event.
  • All analyses compared patients based on the access they achieved, irrespective of the access planned or attempted. (For example, the group of people using catheters also included patients in whom a fistula was unsuccessful.)
The findings suggest that if patients using different types of bloodstream access were of similar health, then use of catheters for hemodialysis has the highest risks for death, infections, and compared with other vascular access types, and fistulas have the lowest risk. Unfortunately, patients in these studies were not of similar health: those using catheters were likely sicker and those with fistulas were likely healthier.

"Our findings are reflected in current clinical practice guidelines, which promote fistulas as the preferred form of bloodstream access in hemodialysis , said Dr. Ravani. He added that the studies they identified were of low quality, though. "Better-quality data are needed, but not from studies with the same design as those already available. In fact, our cumulative meta-analysis shows that this information was already available 10 years ago," he explained.

Explore further: Use of fish oil supplements does not significantly reduce rate of failure of grafts for hemodialysis

More information: The article, entitled "Associations Between Hemodialysis Access Type and Clinical Outcomes," will appear online on February 21, 2013, doi: 10.1681/ASN.2012070643

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.